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Background: Treatment of multiple sclerosis (MS) with disease-modifying drugs (DMDs) 
can reduce relapse frequency and delay disability progression. Although adherence to DMDs 
is difficult to measure accurately, evidence suggests that poor adherence is common and can 
compromise treatment success. There are likely to be multiple factors underlying poor   adherence. 
To better understand these factors, the global MS Choices Survey investigated patient and physi-
cian perspectives regarding key aspects of MS diagnosis, treatment adherence and persistence, 
and disease management.
Methods: The survey was conducted in seven countries and involved patients with MS 
(age 18–60 years; MS diagnosis for $1 year; current treatment with a DMD) and physicians 
(neurologist for 3–30 years; treating $15 patients with MS per average month; .60% of time 
spent in clinical practice). Separate questionnaires were used for physicians and patients, each 
containing approximately 30 questions.
Results: Questionnaires were completed by 331 patients and 280 physicians. Several differ-
ences were observed between the responses of patients and physicians, particularly for ques-
tions relating to treatment adherence. Overall, the proportion of patients reporting taking a 
treatment break (31%) was almost twice that estimated by physicians (on average 17%). The 
reasons cited for poor adherence also differed between patients and physicians. For example, 
more physicians cited side effects as the main reason for poor patient adherence (82%), than 
responding patients (42%).
Conclusions: Physicians may underestimate the scale of poor adherence to DMDs, which 
could impact on their assessment of treatment efficacy and result in inappropriate treatment 
  escalation. In addition, disparities were identified between patient and physician responses 
regarding the underlying reasons for poor adherence. Improvements in the dialog between 
patients and neurologists may increase adherence to DMDs.
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Introduction
Multiple sclerosis (MS) is a chronic, heterogeneous, immune-mediated, demyelinat-
ing, neurodegenerative disorder of the central nervous system.1 It is the most common 
cause of neurological disability in young adults,2,3 affecting an estimated 2.5 million 
people worldwide.4 The most common form of MS follows a relapsing–remitting 
course, characterized by episodes of neurological dysfunction followed by remission, 
often with increased levels of residual disability.5,6 Although MS is currently incurable, 
several disease-modifying drugs (DMDs) are available to reduce relapse frequency and 
severity, and to control disease progression. Most require parenteral administration.
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To gain the full potential benefit from treatment for any ill-
ness, including MS, patients need to adhere to their prescribed 
regimen. The World Health Organization (WHO) defines 
adherence as “... the extent to which a person’s behaviour – 
taking medication, following a diet, and/or executing lifestyle 
changes – corresponds with agreed recommendations from a 
healthcare provider”.7 The concept of adherence requires the 
individual to accept the necessity for the medication, and to 
persist with the therapy. Adherence, therefore, recognizes 
the patient as the driver of treatment success,8 whereas the 
term “compliance” refers only to the need for patients to 
follow instructions. Adherence can be described as the sum 
of acceptance, compliance, and persistence.
Adherence to long-term therapy for chronic diseases 
tends to be poor; the WHO estimates that the average rate 
of adherence to medications for chronic diseases is as low 
as 50% in developed countries, and may be even lower in 
developing countries.7 These estimates highlight the fact 
that poor adherence to medication is a serious problem that 
needs to be addressed.
It is difficult to assess accurately the degree of adherence 
in patients receiving chronic treatment, and few studies have 
directly assessed levels of adherence to MS therapy. However, 
evidence suggests that there is a high level of nonadherence to 
DMDs in patients with MS. A survey of 798 patients with MS 
showed that approximately 37% of patients were nonadherent 
to DMDs (defined as having missed one or more injections 
in the previous 4 weeks).9 Another study retrospectively 
calculated the medication possession ratio (MPR; defined 
as the number of days’ supply of disease-modifying therapy 
dispensed divided by the number of days evaluated) for 
6680 patients with MS who had received at least one DMD 
between 1999 and 2008. The analysis found that between 
52% and 62% of patients were adherent to therapy (defined 
as having an MPR $80%).10 A similar database analysis of 
2446 patients found that 60% of patients were treatment 
adherent by the same definition.11
Suboptimal levels of treatment adherence may result in 
suboptimal outcomes. Patients with poor levels of adher-
ence have a higher risk of relapse11,12 and hospitalization 
for MS,11 as well as incurring higher MS-related medical 
costs.11 Additionally, it is important for patients with MS 
to maintain high levels of treatment exposure over the long 
term. Data from the PRISMS (Prevention of Relapses and 
disability by Interferon beta-1a Subcutaneously in Multiple 
Sclerosis) long-term follow-up study showed that patients 
with high levels of exposure to subcutaneous (sc) interferon 
(IFN) β-1a (based on cumulative dose or cumulative time on 
treatment) had lower rates of relapse and Expanded Disability 
Status Scale progression, and were less likely to convert to 
secondary progressive MS than were patients with low levels 
of exposure to sc IFN β-1a.13
In order to improve treatment adherence in patients with a 
chronic illness, it is vital to first understand why some patients 
do not take their medication. Several factors appear to interact 
to drive poor adherence in patients with MS. A 2009 study 
found that the most common reason for patients missing 
an injection was simply that they forgot to administer their 
treatment.9 Treatment fatigue was also a factor, with some 
patients reporting that they did not take their medication 
because they did not feel like it.9 Perceived lack of efficacy 
is a leading cause of longer interruptions to MS therapy,14 
and to remain motivated and adhere to therapy, patients need 
to believe in the value of their treatment and the benefits it 
confers.8 As MS is currently incurable, the DMDs used in 
MS are intended to slow disease progression, so if patients 
experience few or no clinical signs of disease, they may 
not appreciate the importance of remaining adherent to 
treatment. On the other hand, some patients do experience 
breakthrough disease while on treatment and consequently 
may perceive their treatment as ineffective and not worth 
taking. In these cases it is unclear as to what extent the signs 
of MS may have worsened without treatment. If patients sub-
sequently become nonadherent, their MS is more likely to be 
  problematic. Adverse events (AEs) associated with treatment 
can negatively affect adherence to and persistence with MS 
therapies.9,14 In the period shortly after treatment initiation, 
patients are particularly at risk of discontinuation of treat-
ment because of AEs. Later AEs become less of a problem 
because many of them diminish with time.15
Given the difficulty of accurately assessing adherence 
and the various factors contributing to poor adherence, it is 
important to better understand the views and experiences of 
both physicians and patients regarding MS therapies. It is 
particularly worth noting that patients’ perception of their 
adherence and general experience with therapy may differ 
from that of their physicians. The MS Choices   Survey was 
commissioned by Merck Serono S.A.  – Geneva, Switzerland 
and performed by GfK Healthcare, London, UK. It investi-
gated patient and physician perspectives on the diagnosis, 
treatment, and management of MS. Further, the survey 
sought to identify any discrepancies between the attitudes of 
patients and those of their physicians. Here, we present the 
findings of the survey associated with treatment initiation 
and continuation, as well as factors influencing treatment 
adherence.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Methods
study design
Recruitment of respondents
Patients and physicians from seven countries (Australia, 
Canada, France, Germany, Italy, Spain, and the UK) were 
recruited. These countries were selected to give a broad over-
view of MS from three different continents and to provide a 
good representation of countries with a high prevalence of 
MS.16 Countries from both northern and southern Europe were 
represented to enable assessment of different regional attitudes 
to treatment. Physicians were recruited via an agency online 
panel; patients were recruited through health care profession-
als, panels, and other sources such as patient associations.
Inclusion criteria for physicians were that they had been 
practicing as a neurologist for 3–30 years, treated at least 
15 patients with MS in an average month, and spent more than 
60% of their time in clinical practice. Physicians completed a 
computer-assisted web interview, with enrollment eligibility 
determined through a series of initial screening questions.
Inclusion criteria for patients were that they were aged 
18–60 years, had a diagnosis of MS made at least 1 year 
previously, and were currently being treated with a DMD. At 
the time of the survey, all available DMDs were administered 
parenterally. Patients who completed the survey were not 
necessarily those treated by the responding physicians.
Data collection
The survey consisted of two questionnaires: one for physi-
cians and the other for patients (Supplementary Tables 1 
and 2). The questionnaires underwent preliminary pilot 
testing in February 2009 to ensure that respondents fully 
understood all questions and that the overall flow of the 
survey was logical and conducive to research aims.
The data were mainly collected between May and June 
2009. Data collection complied with international market 
research regulations for reporting AEs associated with MS 
therapy, thus ensuring that any previously undisclosed side 
effects of treatment were acknowledged and that the market-
ing authorization holders were informed accordingly.
Patients completed a semistructured paper-based question-
naire over approximately 20 minutes. The patient survey com-
prised 35 closed questions (each with 2–12 possible responses) 
and two “free-text response” questions. The physicians’ ques-
tionnaire was completed online in approximately 15 minutes 
and comprised 24 closed questions (each with 2–9 possible 
responses; multiple responses were possible for some ques-
tions) and five questions that required   physicians to estimate 
the percentage of their patients involved in each case.
Both questionnaires explored elements of MS diagnosis, 
treatment, and disease management to obtain greater detail on 
key areas, such as the current needs and future developments 
of treatment for MS. Research was coordinated by an inter-
national health care market research agency, which collated 
responses from the survey into a wider research database, 
and conducted detailed analysis to generate qualitative and 
quantitative outputs.
Results
Demographics
In total, 280 physicians completed the survey (Australia, 
n = 10; Canada, n = 20; France, n = 50; Germany, n = 50; 
Italy, n = 50; Spain, n = 50; UK, n = 50). Questionnaires 
were completed by 331 patients (Australia, n = 30; Canada, 
n = 51; France, n = 50; Germany, n = 50; Italy, n = 50; Spain, 
n = 50; UK, n = 50).
Patient involvement in treatment 
decisions
In total, 58% (161/280) of physicians believed that patients 
should select their treatment in partnership with their medi-
cal team; however, when asked “How involved are your 
MS patients in the treatment decision-making process?”, 
only 47% (131/280) of these physicians stated that their 
patients were fully involved. This proportion varied among 
countries, with Canada (75%; 15/20) appearing to have 
the highest level of patient involvement in the decision-
making process, followed by the UK (62%; 31/50). This 
proportion was lowest in Spain, where only 20% (10/50) 
of physicians stated that their patients were fully involved 
in the process.
Overall, 23% (77/331) of patients felt that they had 
discussed treatment options with their medical team, and 
had themselves been responsible for the selection of their 
treatment. Canada (53%; 27/51) had the highest propor-
tion of patients selecting their own treatment, followed 
by the UK (30%; 15/50), Germany (24%; 12/50), France 
(20%; 10/50), Australia (13%; 4/30), Spain (12%; 6/50), 
and Italy (6%; 3/50). Twenty-eight percent (93/331) of 
patients reported that their physician or nurse had selected 
their treatment without any patient discussion. Regardless 
of their involvement in the selection of their therapy, most 
patients (89%; 295/331) reported being aware of both 
the benefits and possible side effects of their current MS 
treatment, and being aware of the existence of other MS 
therapies (84%; 278/331).Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Timing of treatment initiation
There were considerable differences between responses from 
physicians and patients to questions regarding the timing of 
treatment initiation. The findings from the physician and 
patient questionnaires regarding time between diagnosis and 
treatment initiation, by country, are presented in Table 1.
Across all seven countries, 86% (241/280) of physicians 
responded that, on average, treatment was initiated (phar-
macotherapy/DMDs) within 6 months of diagnosis; 4% 
(10/280) stated that they generally initiated treatment more 
than 12 months after a diagnosis of MS. Physician response 
to this question varied across countries, with 96% (48/50) of 
physicians from Germany reporting that they initiate therapy 
within 6 months of diagnosis, compared with 68% (34/50) 
of those from the UK. In contrast, only 51% (169/331) of all 
patients reported starting treatment within 6 months of their 
diagnosis. The corresponding proportion from Germany was 
50% (25/50) and from the UK 34% (17/50). Furthermore, 
36% (120/331) of patients said that their treatment was initi-
ated more than 12 months after diagnosis. Patient responses to 
this question also varied across countries: Spain had the high-
est proportion of patients (50%; 25/50) reporting initiating 
Table 1 initiation of disease-modifying drugs (DMDs): patient and physician responses, by country
Physician question:
On average, how long following the diagnosis of Ms do you usually start to actively treat a patient with pharmacotherapies/DMDs?
Patient question:
how long following your diagnosis did you start undergoing treatment for your Ms?
Within 2 months Within 3–6 months Within 7–12 months Greater than 12 months
Physician (%) Patient (%) Physician (%) Patient (%) Physician (%) Patient (%) Physician (%) Patient (%)
Australia 80 37 10 10 0 13 10 40
canada 45 31 45 22 10 12 0 35
France 48 42 44 20 2 12 6 26
germany 64 24 32 26 4 10 0 40
italy 56 42 34 30 8 12 2 16
spaina 38 22 44 16 16 10 2 50
UK 24 14 44 20 24 18 8 48
Overall 47 30 39 21 10 12 4 36
Notes: a2% of patients responded ‘Don’t know’; n = 331 for total patients; n = 280 for total physicians.
Table 2 summary of treatment interruptions and discontinuations: patient and physician responses, by country
Physician questions:
1.   Approximately what percentage, if any, of all your treated Ms patients take a treatment break?
2.   Approximately what percentage, if any, of all your treated Ms patients stop their treatment?
Patient questions:
1.   have you ever taken a break from your Ms treatment, ie, where you have actively decided not to take your treatment 
as opposed to forgetting to take it and which could last 1 day or longer?
2. have you ever stopped taking your Ms treatment?
Patients taking a break from treatment 
(mean scores)
Patients discontinuing treatment 
(mean scores)
Physician (%) Patient (%) Physician (%) Patient (%)
Australia 17 47 12 30
canada 17 37 14 27
France 15 44 10 26
germany 18 16 15 10
italy 20 40 13 18
spain 14 18 12 12
UK 18 20 17 12
Overall 17 31 14 19
Notes: n = 331 for total patients; n = 280 for total physicians.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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therapy more than 12 months after diagnosis, compared with 
16% (8/50) from Italy.
Treatment interruptions  
and discontinuations
Table 2 provides a summary of patient and physician responses, 
by country, of treatment breaks and discontinuations.
On average, physicians estimated that approximately 
17% of all their treated patients with MS take a break from 
treatment, and that 14% discontinue treatment altogether. 
In contrast, 31% of responding patients reported having taken 
a deliberate break from treatment of 1 day or longer, and 
19% reported that they had stopped taking their MS treat-
ment   completely. The proportion of patients having taken a 
break from treatment was highest in Australia (47%; 14/30) 
and lowest in Germany (16%; 8/50). Almost all physicians 
in this survey reported having at least one patient who had 
taken a break from and/or stopped their MS therapy (93%; 
260/280 and 98%; 273/280, respectively). More than half of 
physicians (59%; 166/280) responded “No” to the question 
“In general, do you find compliance an issue when treating 
MS patients?”
Physicians who reported having patients taking a break 
from, or discontinuing, treatment (n = 277) ranked “Side 
effects (in general)” as the main reason that patients may take 
a break or stop their MS treatment (82% of respondents), 
followed by “Disease showing no sign of decline” (54% of 
respondents; see Figure 1).
Only 42% of patients who reported taking a treatment 
break or stopping their treatment (n = 113) cited “Side 
effects from the treatment” as the main reason for this 
change, followed by being “Emotionally/mentally drained/
fed up with the treatment”, “Practical issues from taking 
the treatment”, and “The treatment was not working” (see 
Figure 2).
Overall, just over half (56%; 187/331) of all patients in 
this survey reported discussing aspects of their MS treat-
ment other than side effects with their physician or nurse, 
although this varied considerably across the different coun-
tries involved. For example, 84% (42/50) of UK patients 
reported taking this action compared with 37% (11/30) of 
Australian respondents.
Discussion
This study was designed to assess physicians’ and patients’ per-
ceptions of the management of MS and their attitudes towards 
treatment. It is generally accepted that good patient–physician 
communication can help to maintain a patient’s motivation 
for, and adherence to, DMD therapy.17 The findings reported 
in this study suggest that there is often substantial disparity 
between the views of physicians and those of patients with MS, 
underlining the need for open communication and cooperation 
between the patient and the health care team.
There is evidence that the benefits of DMDs are greatest 
when treatment is started early in the disease course.18 In 
the majority of countries participating in this survey, treat-
ment with DMDs was initiated within 12 months of MS 
diagnosis. This finding was not, however, consistent in all 
instances, and there were differences among countries. This 
may be due to cultural differences and variations between the 
health care systems of the countries involved in the survey. 
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Figure 1 Main reasons why patients may take a break or stop their Ms treatment, 
as rated by physicians.
Notes: n = 277 (total number of physicians with patients who had taken a break 
from, or stopped, their Ms therapy). ‘Other’ responses not shown because the 
number of responses was too small.
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Figure 2 Main reasons for taking a break or stopping their Ms treatment, as rated 
by patients.
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Additionally, some physicians advocate a gap of some months 
between diagnosis and treatment initiation, to allow patients 
to assimilate the implications of their diagnosis and to accept 
the need for   treatment. Interestingly, there was considerable 
disparity between the physician and patient responses regard-
ing the proportion of patients waiting over 12 months to initi-
ate treatment, the potential reasons for which are currently   
unknown.
Although the importance of involving the patient in 
therapeutic decision making is widely recognized, one in four 
patients in this study responded that their treatment options 
had not been discussed with them prior to the selection of 
a DMD by their medical team. In some cases this may have 
reflected the preference of patients to allow their physicians to 
make treatment decisions. Additionally, while it is important 
for patients to be engaged in the decision-making process, 
their disease characteristics may, to some extent, dictate 
which therapy is appropriate.
Our results show that, although nearly all physicians rec-
ognized that at least one of their patients had taken a break 
from medication, the true scale of nonadherence was generally 
underestimated by physicians, although there was considerable 
variability between countries in the disparity between physi-
cian and patient responses regarding treatment persistence. 
While the degree to which patients adhere to their medication 
regimen is difficult to assess and quantify accurately, this 
study found that gaps in treatment and discontinuation were 
common, a result that is in line with previous data.14,15,19,20 
In this study, the majority of physicians did not find compli-
ance a problem; they felt their patients were able to follow 
  instructions. This, however, would seem to be at odds with 
the finding of a high proportion of patients taking treatment 
breaks.
As previously observed,15 AEs were recognized by 
both patients and physicians as having a negative impact 
on adherence. There is a need for education programs 
aimed at increasing both physician and patient aware-
ness of methods for managing AEs associated with   
DMDs.
Although our study contributes to the understanding of 
the issues facing patients and their physicians regarding the 
treatment of MS, certain limitations must be acknowledged. 
It is difficult to accurately compare the responses of the 
  physicians with those of the patients: the patient population 
was a general sample from each country, rather than from 
the same centers as the physicians. This may have affected 
the finding that patient and physician perceptions differed. 
Furthermore, the inclusion criteria selected for centers 
treating relatively high proportions of patients with MS. 
It is possible that any disconnect between the attitudes of 
physicians and those of patients may be underestimated as 
a result – physicians treating fewer patients with MS may 
be less aware of adherence issues than those who more 
regularly treat MS. In some cases, the questions asked of the 
patients were necessarily different from those asked of the 
physicians, and the two questionnaires were administered in 
two different formats (one written, one completed online). 
Additionally, data are not available to determine any disease 
characteristics that may have led to differences in response. 
Respondents’ interpretation of some of the terms used in the 
questionnaires (such as “compliance”, “treatment break”, and 
“adherence”) may have varied as the terms were not defined 
in the questionnaires. Furthermore, owing to this being an 
international survey, the observed differences in responses 
for some questions may have been a result of regional and 
national variations in health care provision, such as the avail-
ability of certain medications.
At the time of this survey, all available DMDs were 
administered parenterally. It remains to be seen whether the 
recent advent of oral therapies for MS will affect rates of 
treatment adherence, but experience in other therapy areas 
shows that, as with injectable drugs, adherence to oral thera-
pies tends to be suboptimal.21
In summary, these findings not only support previ-
ous suggestions that patient adherence to MS therapy is 
suboptimal, but also highlight that physicians may under-
estimate and undervalue the actual levels of adherence 
among their patients. This underestimation may prevent 
physicians from accurately assessing the efficacy of the 
treatment prescribed, which, in turn, could lead to inap-
propriate treatment escalation in patients who appear to 
be responding poorly to first-line therapy. Improving the 
dialogue between patients and health care professionals 
may support greater adherence to DMD therapy and, ulti-
mately, improve outcomes.
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Table S1 Questions included in physicians’ questionnaire
Physician questions
1. On average, how long following the diagnosis of Ms do you usually start to actively treat a patient with pharmacotherapies/disease-modifying drugs?
  a. Within 2 months
  b. Within 3–6 months
  c. Within 7–12 months
  d. greater than 12 months following diagnosis
2. in general, to what extent do you think patients should be involved in choosing their Ms treatment?
  a. not at all, physician only should make that decision
  b. Treatment options discussed, but ultimately the physician should decide on the best option for the patient
  c. Patients should select their treatment in partnership with their medical team
3. in general, how involved are your Ms patients in the treatment decision-making process?
  a. Fully involved
  b. Fairly involved
  c. not involved at all
4. in your opinion, what are the three most important factors to consider when prescribing an Ms treatment?
  a. effectiveness (based on clinical trials)
  b. Side-effect profile
  c. Long-term safety profile
  d. cost
  e. Other, please specify
5. in your opinion, which three factors do patients consider most important when deciding on a treatment?
  a. Overall efficacy
  b. Side-effect profile
  c. Method of administration
  d. Frequency of treatment
  e. Long-term safety profile
    f. Other, please specify
6. How well do your patients understand the relative benefits and associated risks of currently available MS treatments?
  a. Very well
  b. Fairly well
  c. not very well
  d. not at all well
7. Please indicate what side effects of treatment mainly affect the patients’ adherence to their Ms therapy?
  a. injection-site reactions
  b. Flu-like symptoms
  c. skin-site reactions
  d. Mood changes
  e. Lipoatrophy
    f. chest tightness
  g. increased muscle spasms
  h. shortness of breath
   i. Other, please specify
8. Which side effect of treatment has the greatest impact on adherence to Ms therapy?
  a. injection-site reactions
  b. Flu-like symptoms
  c. skin-site reactions
  d. Mood changes
  e. Lipoatrophy
    f. chest tightness
  g. increased muscle spasms
  h. shortness of breath
    i. Other
9.   For those selecting (a) as a response to question 7 or 8: Approximately what percentage, if any, of all your Ms patients complain of injection-site 
reactions?
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Table S1 (Continued)
Physician questions
10. In general, do you find compliance an issue when treating MS patients?
    a. Yes
    b. no
11. Approximately what percentage, if any, of all your treated Ms patients take a treatment break?
12. Approximately what percentage, if any, of all your treated Ms patients stop their treatment?
13. For those responding with .0% to question 11 or 12: What are the main reasons for patients to take a break or stop their Ms treatment?
    a. side effects (in general)
       b. Disease showing no sign of decline
         c. injection-site reactions
         d. Skin reactions (for example, rash, itching, flushing)
         e. shortness of breath affecting activity levels
      f. not proven to be safe in long-term
    g. cannot afford treatment
         h. Other, please specify
14.   For those responding with .0% to question 11 or 12: Do physical or psychological factors (ie, patient’s belief in his/her Ms treatment) 
predominantly affect the patient’s decision to take a break or stop his/her treatment?
    a. Physical and psychological factors in equal measures
    b. Psychological factors
    c. Physical factors
15. What (other) aspects, if any, do your MS patients generally find challenging about their current treatment regimes?
    a. side effects (in general)
    b. injection-related issues
    c. slow response to treatment
    d. Maintaining a medication schedule
    e. Affording medication
      f. Other, please specify
16.   What do you think Ms patients would cite as the most important factor that would improve their compliance in taking  
the treatment?
    a. no more injections
    b. Taking treatment less frequently
    c. if their medication improves overall well-being
    d. easier to take
    e. Other, please specify
17. if a patient could take the treatment less frequently, how much might the compliance to the treatment change?
    a. Improve significantly
    b. improve moderately
    c. no change/neither deteriorate nor improve
         d. Deteriorate moderately
         e. Deteriorate significantly
18.   Approximately what percentage, if any, of all your treated Ms patients have switched treatments  
(following initial prescription)?
19.   For those responding .0% to question 18: What are the main reasons for patients switching to a new treatment?
    a. side effects (in general)
    b. Improved efficacy
    c. improved injection-site reactions
    d. Less frequent treatment
    e. Greater long-term safety profile
      f. Maintaining a medication schedule
    g. Other, please specify
20. Apart from efficacy, do you regularly review your MS patients’ treatment?
    a. Yes
    b. no
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Table S1 (Continued)
Physician questions
21.   For those responding (a) to question 20: On average, how often do you review the treatment for your  
Ms patients?
    a. More often than every 6 months
    b. Between 6 months but less than 1 year
    c. Between 1 year but less than 2 years
    d. Between 2 years but less than 3 years
    e. Between 3 years but less than 4 years
       f . Between 4 years but less than 5 years
      g. every 5 or more years
    h. Don’t know/varies
22. Approximately what percentage, if any, of all your Ms patients ever initiate a discussion about possible other treatments for their condition?
23.   Would you change your first-line MS treatment for another therapy that a patient may find easier to comply with (yes, would change/no, would 
not change), if it had …
    a. … Greater efficacy
    b. … Fewer side effects
    c. … Greater long-term safety profile
    d. … Different method of administration
    e. … More side effects
      f. … Reduced efficacy
24. What specific information or services, if any, do you offer your MS patients on how they may maintain or improve their overall quality of life?
    a. Moral support/advice
    b. Refer to local Ms support services
    c. support/information from pharmaceutical company
    d. Refer to national/local patient group
    e. Other, please specify
25.   Specifically, what information or services, if any, do you offer your MS patients on helping them cope with the physical disabilities caused  
by their disease?
    a. Refer to a physiotherapist
    b. Refer to the multidisciplinary team
    c. Refer to appropriate healthcare professionals for further assistance
    d. Other, please specify
26.   And specifically, what information or services, if any, do you offer your MS patients on helping them cope with the mental impairments caused  
by their disease?
    a. Refer to a counselor/counseling service
    b. Refer to Ms support services
    c. Refer to multidisciplinary team
    d. Other, please specify
27.   In general, do you think pharmaceutical companies give sufficient consideration with regards to the needs of MS patients when developing  
new treatment options?
    a. Yes
    b. no
28. Which treatment/management innovations do you believe would be likely to benefit MS patients the most if they were available?
    a. Oral therapy
    b. New specific biological therapies
    c. Mobility/disability aids
    d. stem cell transplant
    e. Other, please specify
29.   For those responding (a) to question 28: Why do you say that an oral therapy would be most likely to benefit MS patients if it was available?  
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Table S2 Questions included in patients’ questionnaire
Patient questions
1. how long following your diagnosis did you start undergoing treatment for your Ms?
   a. Within 2 months
  b. Within 3–6 months
  c. Within 7–12 months
     d. greater than 12 months
  e. Don’t know
2. how involved were you in choosing your Ms treatment?
  a. Your doctor/nurse selected your treatment (without discussing any treatment options with you)
  b. Your doctor/nurse and you discussed different treatment options and he/she recommended the one to take
  c. Your doctor/nurse and you discussed different treatment options and you decided which one to take
3.   For those responding (b) or (c) to question 2: When you were discussing with your doctor/nurse which Ms treatment to take, what were the 
most important factors for you to consider?
  a. how effective the treatment would be
  b. Possible side effects from taking the treatment
  c. how the treatment would be taken
  d. how it could affect your quality of life
  e. Long-term safety profile of the treatment
   f. Other, please specify
  g. Don’t know
4.   For those responding (b) or (c) to question 2: Please rate how important each of the following factors were to you when deciding which Ms 
treatment to take? (scale from 1 = ‘not at all important’ to 5 = ‘extremely important’)
  a. how effective the treatment would be
  b. Possible side effects from taking the treatment
  c. how it could affect your quality of life
  d. how the treatment would be taken
  e. Long-term safety profile of the treatment
         f. Other, from Q3
5. Are you aware of both the benefits and possible side effects of your current MS treatment?
  a. Yes, you know both the benefits and side effects
  b. No, you only know the benefits
  c. no, you only know the side effects
  d. no, you do not know about either
  e. Don’t know
6. For those responding (a) or (b) to question 5: What do you consider are the three main benefits from taking your current MS treatment?
  a. Longer between/less frequency of attacks/episodes/flare-ups
  b. Reduction of progression of the disease
  c. Maintains current status/condition
  d. Decrease in severity of attacks/episodes/flare-ups
  e. Prevents symptoms getting worse
   f. Long-term disability is reduced/prolongs time to long-term disability
  g. Long-term safety profile
     h. Other, please specify
       i. Don’t know
7. Apart from what you are currently taking, are you aware of any other available Ms treatment(s)?
  a. Yes
  b. no
  c. Don’t know
8. For those responding (a) to question 7: How much do you know about the benefits and possible side effects of other MS treatment(s)?
  a. You know a lot about them
  b. You know something about them
  c. You know little about them
  d. You know nothing about them
  e. Don’t know
9. have you ever experienced any side effects from your Ms treatment?
  a. no
  b. Yes
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Table S2 (Continued)
Patient questions
10.   For those responding (b) to question 9: have these side effects from your Ms treatment affected your  
daily life?
    a. no
    b. Yes
11.   For those responding (b) to question 10: Which side effects from your Ms treatment have affected your daily life  
the most?
    a. Flu-like symptoms
    b. Tiredness/lethargy
    c. injection-site reactions (eg, redness, soreness, scarring)
         d. Mood changes
    e. Lack of sleep/difficulty sleeping
      f. Skin reactions (itching, rash, flushing of skin)
        g. increased muscle spasms
      h. chest tightness
               i. shortness of breath
                  j. Other, please specify
    k. Don’t know
12.   For those responding (c) to question 11: To what extent do injection site reactions affect your daily life? (scale from 1 = ‘slightly affected’ to  
5 = ‘greatly affected’)
13.   have you ever taken a break from your Ms treatment, ie, where you have actively decided not to take your treatment as opposed to forgetting 
to take it and which could last 1 day or longer?
        a. Yes
    b. no
14.   have you ever stopped taking your  
Ms treatment?
        a. Yes
    b. no
15.   For those responding (a) to question 13 or 14: What led to your decision to take a break or stop your  
  Ms treatment?
    a. Physical factors
    b. Psychological factors
        c. Physical and psychological factors in equal measures
         d. Don’t know
16.   For those responding (a) to question 13 or 14: Specifically, what were the main reasons for taking a break or stopping your  
Ms treatment?
        a. side effects from the treatment
    b. The treatment was not working
        c. Practical issues from taking the treatment
         d. Difficulty in remembering to take the treatment
    e. convenience
                f. Treatment was not proven to be safe over long-term use
        g. Other, please specify
         h. Don’t know
17.   For those responding (a) to question 16: Specifically, what side effects did you experience which made you take a break or stop your MS 
treatment?
        a. Tiredness/lethargy
    b. injection-site reactions (eg, redness, soreness, scarring)
    c. Flu-like symptoms
    d. Skin reactions (itching, rash, flushing of skin)
    e. Mood changes
        f. shortness of breath
        g. increased muscle spasms
    h. chest tightness
         i. Lack of sleep/difficulty sleeping
             j. Other, please specify
           k. Don’t know
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Table S2 (Continued)
Patient questions
18. What do you consider is the most difficult aspect of taking your current MS treatment?
    a. Fitting the injection around your lifestyle (work, holiday, leisure, etc)
       b. Doing your daily activities while trying to manage the side effects from taking the treatment
    c. Being physically able to inject it
       d. Being emotionally able to inject it
         e. Managing the emotional side effects from taking the treatment
            f. Practically managing the injections (storage, disposing of needles, etc)
    g. none in particular
         h. Don’t know
19.   Apart from any side effects of the Ms treatment that you may have experienced, do you ever discuss any other aspect of your Ms treatment  
with your doctor/nurse?
    a. Yes
         b. no
    c. Don’t know
20.   What do you consider are the most important factors concerning your Ms treatment that can help improve  
your quality of life?
    a. no more injections/take alternative form of treatment
    b. Good safety profile when used over a long period of time
    c. none or fewer side effects
    d. Less frequent dosing
21.   Please rank these factors in order of their importance with regards to their affect on improving your likelihood to take your Ms treatment  
(rank 1 to 4: 1 being ‘most important’, 4 being ‘least important’)
    a. no more injections/take alternative form of treatment
    b. Good safety profile when used over a long period of time
    c. none or fewer side effects
    d. Less frequent dosing
22. how much would your life in general change if you could take your treatment less frequently?
    a. Improve significantly
    b. improve moderately
    c. no change at all
    d. Worsen
         e. Don’t know
23. how much would your emotional well-being change if you could take your treatment less frequently?
    a. Improve significantly
         b. improve moderately
    c. no change at all
    d. Worsen
         e. Don’t know
24.   What sources or services, if any, do you use to get more information on how to manage your Ms treatment  
more effectively?
    a. neurologist
         b. Ms society/associations
    c. Additional online source/website
         d. Literature (books, magazines, etc)
    e. general practitioner (gP)
            f. Ms nurse
    g. Family/friends
         h. Literature from pharmaceutical/drug company/manufacturer
                i. Pharmaceutical/drug company/manufacturer’s website
                j. Other, please specify
    k. none
              l. Don’t know
25. Does your doctor/nurse regularly review your Ms treatment?
    a. Yes
         b. no
    c. Don’t know
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Table S2 (Continued)
Patient questions
26.   For those responding (a) to question 25: On average, how often does your doctor/nurse review your  
Ms treatment with you?
    a. More often than every 3 months
                      b. every 3–6 months
    c. every 7–9 months
    d. every 10–12 months (once a year)
    e. every 13–23 months
    f. Once every 24 months (2 years)
    g. Less often than once every 2 years
    h. Don’t know
27. have you ever initiated a discussion with your doctor/nurse about other Ms treatments?
    a. Yes
    b. no
    c. Don’t know
28. have you ever asked your doctor/nurse to change your Ms treatment?
    a. Yes
    b. no
    c. Don’t know
29.   For those responding (a) to question 28: What was your doctor’s/nurse’s response to your request to change your Ms treatment? What did  
he/she say and do? (Free text response)
30.   in general, to what extent, if at all, has your physical well-being been affected by  
your Ms?
    a. improved
    b. not changed
    c. Worsened moderately
    d. Worsened significantly
           e. Don’t know
31. in general, to what extent, if at all, has your emotional well-being been affected by your Ms?
    a. improved
    b. not changed
    c. Worsened moderately
    d. Worsened significantly
     e. Don’t know
32. in general, how much has your Ms affected your overall quality of life?
    a. improved
    b. not changed
    c. Worsened moderately
    d. Worsened significantly
     e. Don’t know
33.   Which new treatment/innovation do you believe would be likely to benefit you the most, as an MS patient,  
if it was available?
    a. Oral therapy (tablet/capsule/pill, etc)
    b. stem cell therapy/transplant
    a. Monthly or annual intravenous injections/infusion
     b. new monoclonal antibodies
    c. Other
     d. Don’t know
34.   Do you think pharmaceutical/drug companies give sufficient consideration to the needs of MS patients when developing  
new treatments?
    a. Yes
     b. no
     c. Don’t know
35. For those responding (b) to question 33: Why do you say that? (Free text response)
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Table S2 (Continued)
Patient questions
36.   For those responding (a) to question 33: Why would an oral therapy benefit you  
the most?
      a. no more injections
    a. Take treatment less frequently
         b. easier to take/remember to take
    c. Other
     d. Don’t know
37.   if an oral treatment was available but less effective than the current injectable forms, if you had the choice, would you prefer to take either the 
oral or injectable form?
    a. injectable form
       b. Oral form
    c. no preference/don’t mind either
     d. Don’t know